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Objective?We aimed to examine the efficacy and the safety of venlafaxine extended release ?venlafaxine-XR?, and 
its effect on the quality of life in patients with generalized anxiety disorder. Methods?Fifty three patients who had 
generalized anxiety disorder were recruited for this study. They showed scores of 18 or higher on the Hamilton 
Rating Scale for Anxiety ?HAMA? and did not have major depression. They were scheduled to be examined 5 
times ?at baseline, 4, 8, 16 and 24 weeks? and took venlafaxine-XR for 24 weeks with a flexible dosing schedule. 
The primary efficacy variables were the response and remission rates ?response?more than 50% reduction from 
baseline in HAMA total score?remission?HAMA total score?7?. Other variables were the Hamilton Rating Scale 
for Depression, Beck Anxiety Inventory, Sheehan Disabilities Scale ?SDS?, and World Health Organization Quality 
of Life Assessment Instrument-Brief Form ?WHOQOL-BREF?. Also, the evaluation on adverse effects was per-
formed. Results?The number of patients who completed 24 weeks of treatment was 32 ?60.4%?. Twenty one 
patients who were dropped out included 8 patients with intolerable adverse effects and 7 patients with unsatisfac-
tory treatment response. Response/remission rates were 43.4/32.1% in the last-observation-carried-forward methods 















toms during 24 weeks on all efficacy measures. By a completed patient analysis, venlafaxine-XR also significantly 
improved the disability scores on SDS and the quality of life scores on WHOQOL-BREF. In this study, nausea, 
palpitation, and severe tremor were common reasons of venlafaxine-XR discontinuation in GAD patients, but any 
serious adverse effect did not occur. Conclusion?Treatment with venlafaxine-XR was effective and well-tolerated 
for the patients with GAD, and also improved quality of life in the GAD patients. (Korean J Psychopharmacol 2006; 
17(1):50-59) 
 



























































































































































































































결     과 
?
1. 환자 및 치료의 특징 
????????????????????????????
Table 1. Characteristics of patients and clinical findings according to treatment 
Follow up ?week? 0 4 8 16 24 
?mg/d? 48.10?17.07 90.23?36.72 108.62?51.44 113.84?49.46 115.38?46.14 Dosing 
?range? ?37.5?75? ?37.5?150? ?37.5?225? ?37.5?225? ?37.5?225? 
Follow-up No. ?%? 53 ?100%? 40 ?75.5%? 36 ?67.9%? 33 ?62.3%? 32 ?60.4%? 
Patents No. of Male/Female 18/35 14/26 12/24 11/22 10/22 
Cumulative No. ?%?  13 ?24.5%? 17 ?32.1%? 20 ?37.7%? 21 ?39.6%? 
Adverse effects   7 7 8 8 
Unsatisfactory response  3 5 7 7 
Failure to return  3 4 4 5 
Follow-up  
loss 
Other reasons  0 1 1 1 










































Table 2. Rates of the response and remission 
Follow up ?week? 4 8 16 24 
Response  17.0% 39.6% 37.7% 43.4% LOCF analysis 
?N?53? Remission  01.9% 17.0% 26.4% 32.1% 
Response  22.5% 58.3% 60.6% 71.9% Observed case 
analysis ?N?32? Remission  02.5% 25.0% 42.4% 53.1% 
      
Table 3. Change of scores from baseline to endpoint on psychological scales and quality of life scales in the total
patients 
  Baseline Endpoint t p 
Hamilton Rating Scale for Anxiety 27.57?08.10 16.57?10.64 ?7.455 0.000 
Hamilton Rating Scale for Depression 15.92?04.78 09.57?06.18 ?7.129 0.000 
Beck Anxiety Inventory 32.27?10.80 21.09?13.38 ?6.622 0.000 
Sheehan Disabilities Scale 18.36?05.71 11.52?06.61 ?6.364 0.000 
WHOQOL-BREF 66.33?11.58 70.67?10.82 ?3.507 0.001 
Physical health 09.88?02.34 11.31?02.48 ?4.490 0.000 
Psychological health 09.43?02.70 10.19?02.74 ?2.867 0.007 
Social relations 10.57?02.74 10.98?02.11 ?1.280 0.208 
Environmental resource 11.17?02.48 11.19?02.51 ?0.092 0.927 
WHOQOL-BREF?World Health Organization Quality of Life Assessment Instrument Brief Form 






























Figure 1. Change of adjusted mean scores in psycholo-
gical scales. BAI?Beck anxiety inventory, HAMA?Hamil-
ton Rating Scale for Anxiety, HAMD?Hamilton Rating 
Scale for Depression. Repeated measured analysis ?Ob-
served case analysis, N?32?. Significantly different from 
only baseline ??? or from both baseline and previous 










































































Figure 2. Kaplan-Meier one-minus survival curve for res-


























Figure 3. Change of adjusted mean total and area sco-
res in the WHOQOL-BREF quality of life scale. WHOQOL-
BREF?World Health Organization Quality of Life Assess-
ment Instrument-Brief Form. Repeated measured analysis 
?Observed case analysis, N?32?. Significantly different 
from only baseline ??? or from both baseline and pre-

















Figure 4. Change of adjusted mean scores in the Shee-
han Disability Scale ?SDS?. Repeated measured analysis 
?Observed case analysis, N?32?. Significantly different 
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